RGNX
REGENXBIO Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 REGENXBIO reported financial results for Q4 and full year 2025, show…
- Mar 10 ▼ 1 insider sell $53.0K at $10.35
- May 11 ▼ 1 insider sell $168.7K at $11.02
- May 14 REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/…
- Jun 29 to Jul 2 ▼ 3 days of insider sells: $718.2K by 1 insider, avg $12.28
- Jun 29 ▲ REGENXBIO announced the first patient dosing in the Phase IIb/III NA…
- Jul 17 ▼ REGENXBIO priced a $100M underwritten public offering of 10M shares…
- Jul 20 ▼ REGENXBIO priced a public offering of 10,003,889 shares of common st…
- Aug 6 ▲ REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs…
- Aug 24 Trading halt: Trading Halt: RGNX, T1 (News Pending)
- Aug 26 to Aug 27 ▲ 2 days of insider buys: $949.4K by 1 insider, avg $9.25
- Oct 5 Mizuho initiates
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider bought $949.4K at an average $9.25. 1 insider sold $940.0K. Price is 21% below their cost.
- InstitutionsBULLISH
Q3 2026: 33 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
16 of 18 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +1.4% to 10.18M shares. 8.3 days to cover, ≈15.4% of shares.
- TrendRANGE
4% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 5.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | ADD | $26.5M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $19.9M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $11.9M |
| Nuveen, LLC | ADD | $7.6M |
| MARSHALL WACE, LLP | TRIM | $6.6M |
| Hudson Bay Capital Management LP | ADD | $3.3M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $3.2M |
| FRANKLIN TEMPLETON INC | DOUBLED | $2.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +160%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 5, 2026 | Mizuho INITIATE | Outperform |
| Aug 25, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 25, 2026 | Baird MAINTAIN | Outperform |
| Aug 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 7, 2026 | Barclays DOWNGRADE | Equal-Weight |
| Jun 24, 2026 | HC Wainwright & Co. REITERATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Christmas Patrick J. Chief Strategy & Legal Officer Nov 1, 2026 | AWARD | 34,722 sh |
Chan Mitchell Chief Financial Officer Nov 1, 2026 | AWARD | 24,305 sh |
Malzahn Craig Chief Technology Officer Nov 1, 2026 | AWARD | 27,777 sh |
PAKOLA STEVE Chief Medical Officer Nov 1, 2026 | AWARD | 34,722 sh |
Malzahn Craig Chief Technology Officer Sep 1, 2026 | TAX W/H | $2.2K |
Chan Mitchell Chief Financial Officer Sep 1, 2026 | TAX W/H | $45.7K |
Ciongoli Gregory Austin Director Aug 27, 2026 | BUY | $499.7K |
Ciongoli Gregory Austin Director Aug 26, 2026 | BUY | $449.7K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Aug 24, 2026 | Resumption Scheduled | Resumed |
SecBot reports
14 filings · 1 press release · 3 bullish · 2 bearish · 2 mixed · 7 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corp. filed a new SC 13G disclosing a 4.8% passive stake in REGENXBIO Inc…
State Street's passive stake at 4.8% is just below the 5% threshold, suggesting routine index or custody holdings rather than a high-conviction bet. Monitor upcoming 13F filings for any material…
- BEARISH 8-KNov 5, 2026
REGENXBIO reported Q3 2026 revenue of $9.2M, well below the $10.7M consensus, and a GAAP net loss…
The revenue miss and steep decline from ZOLGENSMA patent expiration are the headline negatives, but the narrower loss and cash runway into late 2027 provide a buffer. The key catalyst is the…
- NEUTRAL INST-CLUSTERNov 4, 2026
A small institutional cluster in RGNX shows mixed conviction: three asset managers added tiny…
The cluster is dominated by two large trims from Dimensional and Assenagon, but the insider buying of nearly $1M suggests management sees value. Monitor upcoming Q3 earnings and any pipeline…
- NEUTRAL 8-KOct 16, 2026
Director Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new…
Monitor for any subsequent changes in board composition or governance policies, but no immediate catalyst from this filing.
All RGNX filing & press-release reports (15)
- SC 13G reportNov 10, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 4, 2026
- 8-K reportOct 16, 2026
- SC 13G reportOct 13, 2026
- INSIDER-BUY reportAug 27, 2026
- 8-K reportAug 25, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJul 20, 2026
- PRESS-RELEASE reportJul 17, 2026
- 8-K reportJun 29, 2026
- 8-K reportJun 3, 2026
- 8-K reportMay 14, 2026
- 8-K reportMar 5, 2026